ArticleAmerican journal of preventive cardiology2027
Temporal changes in lipoprotein(a) after acute coronary syndrome.
Article in American journal of preventive cardiology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Lipoprotein(a) [Lp(a)] is an established independent risk factor for atherosclerotic cardiovascular disease and is traditionally considered stable. Its behavior following acute coronary syndrome (ACS) and clinical implications remain unclear. This study aimed to characterize the temporal trajectory of Lp(a) following ACS, evaluate whether baseline levels predict longitudinal changes, and assess the stability of clinically relevant Lp(a) risk categories. Methods: In this prospective study, 225 patients with ACS underwent serial Lp(a) measurements during hospitalization and at follow-up (≥6 months). Longitudinal changes were assessed using linear mixed-effects models. Associations between baseline Lp(a) and changes over time were evaluated using Spearman correlation. Stability of Lp(a) threshold risk categories (<50, 50-105, ≥105 nmol/L) was assessed by examining transitions across categories. Results: Lp(a) increased following ACS (p < 0.001), peaking at Days 4-7 (+30.0 %, p = 0.0001) and remaining elevated at Day 30 (+15.0 %, p = 0.0042), before returning to baseline at follow-up. Among individuals with increases in Lp(a), baseline Lp(a) was the strongest determinant of trajectory, with higher levels associated with greater increases at all timepoints (ρ 0.37-0.63, all p < 0.05). Categories for those evels in the low (<50 nmol/L) and high (≥105 nmol/L) categories remained stable with minimal reclassification. Variability was confined to levels in the intermediate range (50-105 nmol/L), where 37.5 % transitioned to ≥105 nmol/L. Conclusions: Lp(a) rises transiently after ACS and returns to baseline over time. Levels in the high and low risk categories remain in those categories, while variability is limited to the intermediate range. A single Lp(a) measurement obtained during ACS may be sufficient for individuals with clearly low or markedly elevated Lp(a) levels, whereas repeat testing after clinical stabilization may be considered for patients with intermediate or borderline baseline levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.